Canada OKs Early Lung Cancer Test
Posted on: Monday, 21 August 2006, 15:00 CDT
Perceptronix said Monday it has been granted approval in Canada for its ClearSign Early Lung Cancer Test
The company said it got approval in May to market the diagnostic device in Europe.
The test works by measuring DNA in thousands of lung cells collected from induced sputum, or the fluid from a deep cough, and is designed for use on patients who are already suspected of having the disease due to a history of heavy smoking, have been exposed to an industrial carcinogen, or have had an indicative imaging result.
ClearSign helps identify who should be further evaluated via more conclusive tests like bronchoscopy or radiography.
The clinical trial results show that, unlike many of the other lung cancer detection technologies, ClearSign Sputum Test sensitivity is virtually independent of tumour stage (early versus late), location (peripheral versus central airways) and cancer histological type (squamous cell versus adenocarcinoma or small cell cancer), said Roger Kemp, Perceptronix's director of detection products.
Source: United Press International
Related Articles
- New Local TV Ad Campaign To Educate Memphis Women About Cervical Cancer Prevention and HPV Testing
- New Local TV Ad Campaign To Educate St. Louis Women About Cervical Cancer Prevention and HPV Testing
- Detecting Colon Cancer With A Simple Blood Test
- Lung Cancer Detection With Blood Test
- Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
- View Details on the Top 20 Companies With Products in the Early Stage of Development for Non-Small-Cell Lung Cancer, Lung Cancer or Small Cell Lung Cancer
- New Painless Test for Cervical Cancer Outperforms Tissue Sample Tests
- This Week on Your Cancer Today: New Genomic Test Announced By Duke University
- Cancer Vaccines in Final Test Phase
- Interstitial Lung Disease, Lung Cancer, Lung Transplantation, Pulmonary Vascular Disorders, and Sleep-Disordered Breathing in AJRCCM in 2004
 |
 |
User Comments (0)
RSS Feeds